Vinblastine Sulfate

Vinblastine Sulfate
Product Description

This API is part of the FCC product portfolio

Aspen Healthcare. We Care

  • NL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
Specifications
  • CAS Registry Number
    143-67-9
  • Supplied from
    South Africa

Aspen Healthcare. We Care

  • NL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)

More Products from Aspen Healthcare. We Care (58)

Aspen Healthcare. We Care resources (4)

  • Sponsored Content Aspen API’s Green answer to peptide synthesis

    Our Green Continuous Liquid Phase Peptide Synthesis (GC-LPPS) combines the advantages of the classical solution-phase synthesis with the solid-phase approach. 
  • Brochure Aspen. Healthcare. We Care.

    Aspen is a global specialty and branded pharmaceutical company committed to promoting access to medicines and improving the health of patients across the world through our high quality, affordable products. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.
  • News CPHI Trend Report - Sustainability in Pharma

    While in the past, much of the discussion around sustainability in the pharmaceutical industry rightly focused on efforts to minimize the environmental impact of drug production, the needle has now shifted. There are signs that companies not only understand that it represents one of the world’s biggest challenges moving forward, but also that they are starting to incorporate sustainability practices into a much broader suite of operations.
  • News Pharmaceutical shortages open up debate on reshoring of API manufacturing

    Panel at CPHI Festival of Pharma discusses options for companies to ensure robust supply chains and reduce overseas supply dependency